EUVIMEDEUVIMED entdecken
Crossref

Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

D. Rischin, C.I. Chen, S. Porceddu, F. Day, D. Brungs, H. Christie, J.E. Jackson, B.N. Stein, Y.B. Su, R. Ladwa, G. Adams, S.E. Bowyer und 8 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-05 · 125 (1) · e70-e71

DOI: 10.1016/j.ijrobp.2026.02.143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-05. Verfasst von D. Rischin und 19 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Rischin, D., Chen, C., Porceddu, S., Day, F., Brungs, D., Christie, H., Jackson, J., Stein, B., Su, Y., Ladwa, R., Adams, G., Bowyer, S., Bossi, P., Patel, V., Walker, J., Lim, A., Seebach, F., Yoo, S., Goncalves, P., & Fury, M. (2026). Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). International Journal of Radiation Oncology*Biology*Physics, 125(1), e70-e71. https://doi.org/10.1016/j.ijrobp.2026.02.143

Vancouver

Rischin D, Chen C, Porceddu S, Day F, Brungs D, Christie H, et al. Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC). International Journal of Radiation Oncology*Biology*Physics. 2026;125(1):e70-e71. doi:10.1016/j.ijrobp.2026.02.143

BibTeX
@article{Rischin2026,
  author = {Rischin, D. and Chen, C.I. and Porceddu, S. and Day, F. and Brungs, D. and Christie, H. and Jackson, J.E. and Stein, B.N. and Su, Y.B. and Ladwa, R. and Adams, G. and Bowyer, S.E. and Bossi, P. and Patel, V.A. and Walker, J. and Lim, A.M. and Seebach, F. and Yoo, S.Y. and Goncalves, P. and Fury, M.G.},
  title = {Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {1},
  pages = {e70--e71},
  doi = {10.1016/j.ijrobp.2026.02.143}
}
Kostenlos starten →